SBIR Phase I: Nano Technology Buccal Drug Delivery Platform

该小型企业创新研究（SBIR）第一阶段项目旨在开发一种新型药物递送平台，该平台使用有效的纳米封装方法，能够通过颊粘膜局部和全身递送各种药物。载药纳米颗粒（NP）被保护并容纳在生物基质海绵中，该海绵还可以容纳渗透增强剂和特定的靶向基序。这些组分的组合将导致成功的口腔递送平台，其可以降低毒性，增加功效并显著改善患者依从性和生活质量。该项目的更广泛的影响/商业潜力将是用于不同药物口服给药的新技术，例如化疗剂，抗生素或疫苗。该项目最初将关注口腔癌，因为该适应症，治疗和发展途径将提供最快和最大的许可和商业化机会。然后，可以定制该技术以满足其他市场的特定需求。通过修改NP？的属性和有效载荷，该平台可以针对各种产品，各种疾病和目的进行优化。

This Small Business Innovation Research (SBIR) Phase I project seeks to develop a novel drug delivery platform using an effective nano-encapsulation method capable of delivering a variety of drugs locally and systemically through buccal mucosa. The drug-loaded nanoparticles (NPs) are protected and housed in a bio-matrix sponge, which can also hold permeation enhancers and specific targeting motifs. A combination of these components will result in a successful buccal delivery platform that can reduce toxicity, increase efficacy and significantly improve patient compliance and quality of life.The broader impact/commercial potential of this project wil be a new technology for oral administration of different drugs, such as chemotherapeutics, antibiotics or vaccines, The projects will focus initially is oral cancer because this indication, treatment and developmental path will offer the fastest and greatest chance of licensing and commercialization. The technology can then be customized to meet the specific needs of other markets. By modifying NP?s properties and payloads, the platform can be optimized for variety of products, various diseases and purposes.